Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
His right-hand woman Melissa DeRosa has been responsive to me on Twitter (regarding a separate matter). May be a good way to reach out... https://twitter.com/melissadderosa
Did you also catch where AF hijacked Dr. Yo's thread? Adam seems to be trolling anyone who's seemingly pro-CYDY. I'm dying to know what precisely is behind AF's absolute obsession on CYDY. 8/23 thread her where AF trolls Dr Yo twice:
Wow. Old man Adam plunks himself on Dr. Yo's feed w/ the sole purpose of being obnoxious. Dr. Yo doesn't punch back but replies in a classy, measured way. Adam isn't even sophisticated enough to reply. Douchebag personified.. and that's prob his only path into the promised land
— sara jaye (@sarajaye212) August 26, 2020
Uplisting being driven/handled by Mike Mulholland and attorneys, not NP... not to say that's foolproof but I don't expect dropped balls on the nasdaq application
He is also an advisor to the FDA, and has been a medical advisor for Cytodyn for years.
IF this rumor is true, I'd think that Bruce has many more direct and indirect contacts to the OWS group and subgroups. Would make total sense that a Bruce person strung the meeting together - if that's the case, BP+NP both attending would make very good sense. Either way, true or not, it'd be nice to see the boys in the band back together.
Appreciate this a lot more Monroe1. Thanks.
An update today from Olive re: Holly
(from https://www.gofundme.com/f/HollysCancerDrugTrialCampaign)
by Olive O'Sullivan, Organizer
Good morning from West Cork.
Here is the news!
Our Holly is meet her Oncology team today in St James hospital at 0900 to discuss her Chemotherapy plan .
Her consultant Dr Kennedy is going to plan her future chemotherapy schedule with Holly .
Holly messaged me yesterday to say she is making progress, slowly but moving forward.
Her twice a week #leronlimab was administered yesterday as per her scheduled protocol.
She is researching a European Specialist for another supportive opinion and exploring other supportive treatments we can get our hands on.
For now, we will keep the fundraiser opened to help her in her decision process and to support her in whatever decision she makes - so that it’s one less thing for her to worry about.
She loves being home, with Derek and her little boy Andrew.
She wants to express on here, her profound gratitude to everyone who have stood by her .
She also wanted to reach out and express dismay at the doubts that Adam Feuerstein attempted to undermine in me/you and her decision to choose #leronlimab as her trail drug of choice.
Thankyou again from the bottom of our hearts.
Big hugs from beautiful ( but wet) West Vork today.
Olive x
Sorry but 3x is right on with tonight's posts. NP is charismatic, passionate and works very hard. But come on - he's learning on the job as a CEO and as a biotech player in a very tense world pandemic that is touching on every geopolitical nerve. NP's errors, blabbering and putting of carts-before-horses have made the company lose time, credibility and probably significant dollars. Glad someone has knocked some sense into him regarding tossing out hopeful timelines and relaying nonsense which fuels the Adam Fibbersteins of the world. Were it not for this amazing molecule, I would've walked long ago.
So, yes, they may have a plan, but do they have the mental tools to execute it? I tend to doubt it. My wish is that the current CD10 data and the midpoint of CD12 are enough to spur licensing offers from experienced players who know the drill.
It could very well be ( something I've believed for a while) - they're hoping to time this with other news, whether it be uplist, BP partnering, or data on CD12. There's a reason that they're sitting on this. Behavior change in sputtering out piecemeal news has shifted. Something's up. And I think it's really good.
Adam Feuerstein's bosses on twitter; tell them how you feel: @GideonGil @rickberke
I am demanding answers as to why this is allowed to continue. Started with a tweet. Emails and phone calls are next. If I'm not satisfied, it's on to STAT's advertisers.
Wrong. Patterson is a shareholder. Jay Lalezari is not.
That's a convo that needs to happen. I've also tried to link NP up with PR's I work with. Crickets. May I suggest sending to Scott Kelly and Mike Mulholland? NP may take the suggestion personally as he is a passionate and emotional guy.
Thanks but as a shareholder I'll take action whenever I feel like it. Especially when said ideas could raise the company's profile or encourage a climb in SP. GLTU!
Superb - let's amplify this idea...
Plainly and simply, any company who communicates to the public should have a Public Relations or Communications department - or at the very least, a paid consultant or an agency of record. Not only do those people strategize the communications policies and schedules, they know how to write from the lens of putting the company best-foot-forward in an understandable, translational and concise manner. They also know how to media-train their execs who may be consumer-facing on live television. They also have longstanding media relationships they can leverage on behalf of their clients. Not that deep. It's one of the most important investments that Cydodyn could make.
The author of the article should write CYDY's PR's. Look how clean and concise this is.
Here's my political solution: Patterson/Landstreet 2020.
That is all.
Mike m said it
Plus, if early results can be provided from CD12 to FDA - and if all datasets showed similar promise - could that collective result call for a smaller pool for M/M P3? Is this a possibility?
Patterson to appear on DrBeen - roll to 16:14
https://www.facebook.com/watch/live/?v=1071598326576194&ref=search
Excellent. That makes all the difference. His initial tweet seemed a bit harsh and not at all like his usual enthusiasm for Leronlimab. THANK YOU Smiley Riley
I have a few personal friends - a heart surgeon, a psychiatrist, and a family friend who's a senior exec at a small US Pharma co. In general terms, they told separately me not to be surprised if any promising drug was delayed or suppressed in favor of big Pharma. Not new news, of course, but interesting to hear from people closer to the facts than me. Carry on.
I don't disagree! But if you read the OP again, what I am pointing out is the fact that many weeks ago, NP touted and rambled about the BP paper and how it would be published "next week." FF to today, and he won't touch the topic and says only BP can comment since he is the lead author. Is that not a little strange?
Sorry if my conjecture ruins your ticker tape parade. But it happened, and if you can't find the original video where NP first announced that BP's paper would be published "next week," I will try to find it for you. But it doesn't matter because he owned it, and now won't comment on it. All I expect is a little consistency.
Exactly. Plus, why did he shrug off answering about the Dr. BP preprint? NP said that since BP is the primary author, only he would be attributable to giving an update. But, around 8 weeks ago, it was NP who was directly touting that the paper would be published "next week." Y'all remember that?
Not really a win, sorry. Lenzulimab, not Tocilizumab, is who we need to worry about as a competitor.
I own both. Glad to hear about the spinoff.
This is the post I didn't know I needed today!! Actually laughing out loud to myself.
I'm taking it back to bbcbro's post a week ago as to Trump's forthcoming 'therapeutics' announcement; IMO of course:
ACTIV is planning five master protocol trials, the first of which will test three host-targeted immune modulators against TNFa, CTLA-4 and CCR2/CCR5. The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) consortium is led by NIH and managed by the Foundation for NIH. Its members include 18 biopharma companies, FDA, CDC and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). BARDA is part of ASPR (see “ACTIV Coming into Focus”).
Oh boy... Dr. Pourhassan's going on Dr. Been's facebook live on Saturday night. Dr. Been is incredibly smart and was an early Leronlimab supporter so no shade whatsoever - but how is this appearance going to be helpful to the SP? Ughhh why??? Silence would be so much better for now...
https://www.facebook.com/drbeenmedical
I signed up for Tim Sykes' daily email. We are one of five stocks he mentioned today:
CytoDyn Inc (OTCQB: CYDY)
CytoDyn Inc. is a clinical-stage biotech with several drugs in the pipeline. During the coronavirus pandemic, much of the PR focus has been on leronlimab. In April, the drug showed positive results for treating COVID-19 patients.
On June 19, CytoDyn presented on the Wall Street Reporter’s “Next Super Stock & Investors Discovery Day” livestream. On June 29, CytoDyn and the NIH of Mexico announced a small phase 3 trial for severely ill COVID-19 patients.
The stock kept going. But then the inevitable happened. I was watching this one, waiting for a big morning panic. It came literally as I was writing this. Check this out … It’s a tale of two charts, just minutes apart...
Take a look at the CYDY three-month chart on the day of the panic, before the panic:
Alternate text
CYDY chart: 3-month, daily candle, top penny stocks to watch July 2020 — courtesy of StocksToTrade.com
And now … after the panic…
Alternate text
CYDY chart: 3-month, daily candle, after a big morning panic — courtesy of StocksToTrade.com
That big red candle on the right is the panic. Now take a look at the June 30 intraday chart. Memorize this chart! Study it like crazy.
Alternate text
CYDY chart: June 30 intraday, 1-minute candle, perfect morning panic dip buy — courtesy of StocksToTrade.com
Paul Scolardi Uses This One Simple Pattern
to Trade Stocks From Home…
There's an opportunity to get Paul’s #1 stock trading pattern… and potentially start making trades from home in the next coming weeks…
Click here now before it’s too late
Alternate text
Students report crushing it on this panic both short and long. For me, I bought the dip and made $23,220.*
(*My results are not typical. I have exceptional knowledge and skills developed over time. Trading is risky and most traders lose money. Do your due diligence and never risk more than you can afford.)
So why is this stock still considered a top penny stock to watch in July 2020? Two reasons: first, you need to study this panic. It was PERFECT! Second, the CYDY bounce was huge — back to $8. Plus, it has a history of multi-day runs. I’m watching for another big dip buy opportunity.
Now for the last of our top penny stocks to watch this month...
NP, BP, et al are privy to the data as it comes in. They are NOT privy to whether each dataset comes from Leronlimab pts or placebo pts. NP would never ever have brought this up if be believed that the SAEs came from the dosed pts. This is Nader being Nader.
ut5678 Wednesday, 07/01/20 02:45:32 PM
Re: Amatuer17 post# 89648 0
Post # of 89742
I went back and listened on the severe/critical data. He stated that “quite a few deaths reported as SAE’s”. It doesn’t sound like there were any other SAE’s besides the death. My question is this...does the company know if the reported deaths/SAE’s were actually from patients taking Leronlimab or could some/several be reported from the placebo leg? Info is at the 4:54 mark on the video.
For our purposes, Tocilizumab is a non-starter since it's an IL-6 inhibitor only. Leronlimab targets IL-6 and the CCL5 (Rantes)/CCR5 pathway.
__________________________________
Borel Fields Tuesday, 06/30/20 11:41:01 PM
Re: bobshmob post# 89359 0
Post # of 89432
Some good outcomes on tocilizumab, but not randomized, as paragraph 2 of the Lancet paper notes: "a non-randomly selected subset of patients also received tocilizumab."
No question, the list of possible storm-treating drugs is narrowing to leronlimab (first with randomized trial results), tocilizumab and lenzilumab. And everyone understands we need storm-treating drugs.
Jimmy667, the original post was also mine. I am doing my own DD and was simply digging in after reading the post which said BARDA has a focus on a "CCR2/CCR5" MAb. Prior to this, I was unaware that such a MAb existed. A quick google search led me to the BMS trials. I asked for feedback on my finding. With all due respect, there is no other agenda for me except to become knowledgable on what is my most sizable investment in 10+ years of stock trading.
Count on this - if I find something relevant (good or bad) - I'm gonna post it.
jimmy667 Sunday, 06/28/20 02:43:29 PM
Re: SaraLovesYou post# 88192 0
Post # of 88225
Two reasons the prior BMS trials were discontinued. Safety and Efficacy. One or both. Meanwhile CYDY is hitting on all 24 cylinders for safety and Efficacy. The original post is typical for naysayers to invent some supposed competition to incite FUD. Many many loser drugs and companies have been posted about in such a manner over the years to oppose strong contenders and they have all proven to be pretenders.
The Defense Production Act could fast-track the process and eliminate the usual roadblocks.
Chuckles759 Sunday, 06/28/20 02:00:59 PM
Re: Scooter McCabe post# 88199 0
Post # of 88204
No doubt the line to partner with CytoDyn would suddenly be a mad scramble.
But I recall NP saying that it took over a year to get the tech transfer and processing with Samsung Biologics up to FDA standards. I'm not sure how much of that "process" you can waive or shorten if using another CMO.
It's certainly not like finding that your normal machine shop's lathe is broken and you have to go down the street to their competitor with your blueprints to keep production going. I really wish it were that easy.
Actually five trials are currently recruiting for BMS813160 for various cancers as a combo therapy. Medical folks - can you speak to how this compares to Leronlimab? To recap, BMS813160 targets CCR2/CCR5. Certainly there will be other comparable such as 1L-6 inhibition, etc.
Active trial links: https://clinicaltrials.gov/ct2/results?cond=&term=BMS813160+&type=&rslt=&recrs=a&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=
>>>>>
The only active clinical trial for BMS drug is scheduled for completion in 2015. The other two trials were closed out a few years ago.
Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT03496662 Washington University School of Medicine|Bristol-Myers Squibb|Barnes-Jewish Hospital|National Institutes of Health (NIH)|National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma
August 31, 2018 Phase 1|Phase 2
NCT01049165 Bristol-Myers Squibb
Accelerated Intimal Hyperplasia
February 2010 Phase 1
NCT01752985 Bristol-Myers Squibb
Diabetic Kidney Disease
March 18, 2013 Phase 2
Thanks bbcbro for this deep dive which I inhaled last night - the thing that throws me is that they specifically mentioned "CCR2/CCR5." You correctly state that the only listing on the excel sheet for any chemokine receptor is Leronlimab (line 181). I wanted to see if any CCR2/CCR5 MAbs were in trials and see the Bristol Myers Squibb is actively in five various cancer trials with BMS-813160 (as a combo therapy).
Can someone smarter than me comment as to whether this is a competitor to Leronlimab (as far as Covid indications at minimum)?
trials listed here:https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/ccr2ccr5-antagonist-bms-813160
bbcbro's post:
BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows
According to BioCentury’s COVID-19 Resource Center, there are more than 100 immunomodulators and immunosuppressants in the clinic to treat COVID-19. New entries this week include therapies from Evelo Biosciences Inc. (NASDAQ:EVLO), Theravance Biopharma Inc. (NASDAQ:TBPH) and Fulcrum Therapeutics Inc. (NASDAQ:FULC).
HHS’s Biomedical Advanced Research and Development Authority updated its website early this month to reflect that it is no longer accepting funding proposals for immunomodulators to treat COVID-19, or therapeutics targeting lung repair for the disease. It did not give a reason for the change.
The about-face follows the U.K. approval of anti-inflammatory steroid dexamethasone, which reduced mortality by 35% in ventilated COVID-19 patients (see “Master Protocol Shows Survival Benefit”).
The change also comes as ACTIV -- a COVID-19 consortium that counts BARDA’s parent agency as one of its members -- readies to launch a master protocol of immunomodulators this month.
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) consortium is led by NIH and managed by the Foundation for NIH. Its members include 18 biopharma companies, FDA, CDC and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). BARDA is part of ASPR (see “ACTIV Coming into Focus”).
ACTIV is planning five master protocol trials, the first of which will test three host-targeted immune modulators against TNFa, CTLA-4 and CCR2/CCR5
CCR5 (CD195) - CC chemokine receptor 5
C-C chemokine receptor type 5, also known as CCR5 or CD195
https://www.biocentury.com/article/305582/barda-no-longer-funding-immunomodulators-as-support-for-the-therapeutic-class-to-treat-covid-19-grows
The only CCR-5 inhibitor (there are no CCR-2) in clinical trials? You guessed it.
https://www.biocentury.com/clinical-vaccines-and-therapies
Policy nerds: Can the Defense Production Act be instated for drug manufacture at this time? If they did it for ventilators, could they do it for pharmaceuticals?
Hi all - nice to finally be here rather than lurking only. There are some great minds on this board.
I've been in and out of CYDY for about 2 years but have been unhealthily obsessed with it since March 2020. 26,500 shares across 9 different buys. Cautiously hopeful. GLTA!